0
Verona Pharma plc Banner Image

Verona Pharma plc has reached its limit for free report views

Work for Verona Pharma plc? Upgrade Your Profile and unlock all your annual reports.

Verona Pharma plc

  • Ticker VRNA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Verona Pharma plc Logo Image
  • 11-50 Employees
  • Based in London, England
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combinesMore bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine is in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.
Verona Pharma plc

Most Recent Annual Report

Verona Pharma plc MOST RECENT 2019 Annual Report

Report Locked. Verona Pharma plc has reached its limit for free report views.

Older/Archived Annual Reports